Search results for "LIX"

showing 10 items of 891 documents

The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guideline…

2010

Biological therapies are an important step in the management of Inflammatory Bowel Diseases. In consideration of high cost and safety issues there is the need to have clear recommendations for their use. Despite the American Gastroenterological Association and the European Crohn's and Colitis Organisation have published exhaustive Inflammatory Bowel Disease guidelines, national guidelines may be necessary as cultural values, economical and legal issues may differ between countries. For these reasons the Italian Society of Gastroenterology and the Italian Group for the study of Inflammatory Bowel Disease have decided to elaborate the Italian guidelines on the use of biologics in Inflammatory…

methods Tumor Necrosis Factor-alphaAnti-Inflammatory AgentsUlcerativeDiseaseGUIDELINESHumanized Antibodieetiology Pregnancy Pregnancy ComplicationGastroenterologyInflammatory bowel diseaseetiology Opportunistic InfectionCrohn DiseasePregnancyNeoplasmsMonoclonaldrug therapy Remission Inductionantagonists /&/ inhibitorsSettore MED/12 - GastroenterologiaRemission InductionGastroenterologyAntibodies MonoclonalUlcerative colitisAnti-Inflammatory AgentItalyadverse effects/therapeutic use Intestinal FistulaTumor necrosis factor alphaFemaleImmunosuppressive Agentsmedicine.drugbiological drugsmedicine.medical_specialtyIBDOpportunistic InfectionsAntibodies Monoclonal HumanizedAutoimmune Diseasesadverse effects/therapeutic use Autoimmune DiseaseInternal medicinemedicineAdalimumabIntestinal FistulaHumansColitisdiagnosis/drug therapy/surgery Italy Neoplasmadverse effects/therapeutic use AntibodieHepatologydrug therapy Female Humans Immunosuppressive Agentbusiness.industryTumor Necrosis Factor-alphaAdalimumabCancermedicine.diseaseInfliximabInfliximabdigestive system diseasesdrug therapy Crohn Diseaseetiology ColitiPregnancy ComplicationsColitis Ulcerativebusiness
researchProduct

Impact de la flore adventice sur la rétention des pesticides : développement d’un nouvel indicateur pour l’évaluation des systèmes de culture

2016

Weeds are usually considered as harmful for crops but they are essential for biodiversity. Indicators were already developed using the model FLORSYS (Colbach et al., 2014) to evaluate the cropping system in term of harmfullness or benefits related to weed flora. We thus propose a new indicator to evaluate the potential of pesticide retention by weed flora and its impact on pesticide transfer into the environment. The indicator is divided in two parts i) herbicide application efficiency (herbicides interception by weeds), ii) plant uptake for the others pesticides. Several cropping systems have been simulated with the FLORSYS model. Preliminary results have been analyzed using the tree regre…

modelling[SDV] Life Sciences [q-bio]leachinglixiviationevaluation[ SDV ] Life Sciences [q-bio]évaluation[SDV]Life Sciences [q-bio]système de culturecropping systempesticidemodélisation
researchProduct

Comparison of the acute effects of anti-TNF-alpha drugs on a uveitis experimental model.

2010

To compare histopathological and biochemical effects of the anti-TNF-alpha drugs adalimumab and infliximab in a uveitis experimental model.Histopathological evaluation was performed 24 h after endotoxin (200 microg into the footpad) and drug administration, as well as biochemical analysis of oxidative stress-related markers in the aqueous humor.Severe inflammation was found in rat anterior chamber of the eye 24 h after endotoxin. Only infliximab administration partially prevented the endotoxin-induced disruption of the blood-aqueous barrier, as well as the increase in Rantes and MCP-1 concentration in aqueous humor. Both drugs ameliorated the histopathological score after endotoxin. Biochem…

musculoskeletal diseasesAcute effectsMaleBlood-Aqueous BarrierTime FactorsAnti-Inflammatory AgentsInflammationmedicine.disease_causeAntibodies Monoclonal HumanizedAqueous HumorUveitisAdalimumabImmunology and AllergyMedicineAnimalsskin and connective tissue diseasesCells Culturedbiologybusiness.industryTumor Necrosis Factor-alphaAdalimumabAntibodies Monoclonalmedicine.diseaseInfliximabInfliximabRatsOphthalmologyDisease Models AnimalOxidative StressTreatment OutcomeRats Inbred LewImmunologyMonoclonalbiology.proteinAntibodymedicine.symptombusinessOxidative stressUveitismedicine.drugOcular immunology and inflammation
researchProduct

Adalimumab in active ulcerative colitis: A “real-life” observational study

2013

Abstract Background and aims The effectiveness of adalimumab in the treatment of ulcerative colitis is under debate. Although controlled trials have shown that adalimumab is significantly better than placebo, the absolute clinical benefit is modest. We report data on the effectiveness of adalimumab in a cohort of ulcerative colitis patients treated in 22 Italian centres. Methods All patients with active disease treated with adalimumab were retrospectively reviewed. Co-primary endpoints were clinical remission at weeks 4, 12, 24 and 54. Secondary endpoints were sustained clinical remission, steroid discontinuation, endoscopic remission and need for colectomy. Results Eighty-eight patients we…

musculoskeletal diseasesAdultMaleAdalimumab “Real-life” study Ulcerative colitismedicine.medical_specialtymedicine.medical_treatmentIBDAnti-Inflammatory AgentsAdalimumab; “Real-life” study; Ulcerative colitisAntibodies Monoclonal HumanizedPlaceboCohort StudiesYoung AdultRefractoryAdrenal Cortex HormonesInternal medicineAdalimumabmedicineHumansskin and connective tissue diseases“Real-life” studyRetrospective StudiesColectomySettore MED/12 - GastroenterologiaHepatologybusiness.industryRemission InductionSettore MED/09 - MEDICINA INTERNAGastroenterologyAdalimumabmedicine.diseaseUlcerative colitishumanitiesInfliximabSurgeryDiscontinuationTreatment OutcomeUlcerative colitisCohortColitis UlcerativeDrug Therapy CombinationFemalebusinessmedicine.drug
researchProduct

Infliximab, azathioprine or combination therapy in the treatment of active Crohn's disease.

2010

The treatment of moderate-to-severe steroid-dependent Crohn's disease has been a challenging issue for the gastroenterologist. Until to 10 years ago, immunosuppressors, mainly azathioprine or 6-mercaptopurine, were the best possible treatments available, and remission rates ranged from 30 to 60% according to the results of open studies and controlled trials. Recently, infliximab has been shown to be effective in steroid-dependent patients and, combined with azathioprine, it has been shown to increase 1-year remission rates. A recent large randomized controlled trial comparing infliximab, azathioprine and infliximab plus azathioprine demonstrated that the combination of infliximab plus azath…

musculoskeletal diseasesCrohn's diseasemedicine.medical_specialtySettore MED/09 - Medicina InternaHepatologyCombination therapybusiness.industryGastroenterologyAzathioprinemedicine.diseaseGastroenterologyInfliximablaw.inventionSurgeryRandomized controlled triallawInternal medicinemedicineInfliximab azathioprine Crohnbusinessmedicine.drug
researchProduct

Update on intravitreal anti-tumor necrosis factor alpha therapies for ocular disorders

2014

Abstract Tumor necrosis factor alpha (TNF-?) is an important pro-inflammatory cytokine associated with a variety of ocular diseases. The currently available TNF-? inhibitors are etanercept, infliximab, adalimumab, golimumab, and certolizumab. Experimental and clinical studies on the intravitreal use of these agents have been reported with etanercept, infliximab, and adalimumab: etanercept has shown limited efficacy in scarce reports; infliximab has been associated with local safety concerns but appears to benefit certain cases; adalimumab has shown no efficacy in cases of age-related macular degeneration (AMD) or diabetic macular edema (DME), but the combination with bevacizumab may be effe…

musculoskeletal diseasesOncologymedicine.medical_specialtyPathologygenetic structuresBevacizumabReviewCertolizumabEtanerceptEtanerceptIntravitreal injectionInternal medicineOcular disordersmedicineAdalimumabskin and connective tissue diseasesTumor necrosis factor alphabusiness.industryAdalimumabMacular degenerationmedicine.diseaseInfliximabeye diseasesGolimumabInfliximabOphthalmologyInfectious DiseasesTumor necrosis factor alphasense organsbusinessmedicine.drugJournal of Ophthalmic Inflammation and Infection
researchProduct

Orejas valgas: estabilización mediante colgajo dermo-graso-pericóndrico retroauricular

2013

El tratamiento quirúrgico para la corrección de las orejas prominentes o valgas se basa en crear una distancia de entre 17-21 mm entre el hélix y la mastoides, así como recrear unos pliegues auriculares anteriores bien definidos. Desde finales de 1800 hasta la actualidad se han descrito muchas técnicas para corregir las orejas despegadas, prominentes o valgas, cada una de ellas con sus propias características. En el presente trabajo describimos una técnica para estabilizar el resultado quirúrgico cuando se corrige esta entidad y evitar su recidiva. Se trata de un procedimiento de fijación mastoidea de la oreja mediante un colgajo dermo-graso-pericóndrico de sencillo diseño, útil, seguro y f…

musculoskeletal diseasesPhysicsOtoplastiabiologyAnatomymusculoskeletal systembiology.organism_classificationOrejas prominentesbody regionsValgusOrejas en asaHelixotorhinolaryngologic diseasesSurgerysense organsOrejas valgasCirugía Plástica Ibero-Latinoamericana
researchProduct

Patología articular en la enfermedad inflamatoria intestinal

2005

The joint disorders taxonomically included in the group of seronegative spondyloarthropathies under the generic name of enteropathic arthropathy represent the most frequent extra-intestinal manifestation of inflammatory bowel disease (IBD), affecting 33% of patients. Their frequency is similar to that of ulcerative colitis and Crohn's disease. Enteropathic arthropathy consists of two main joint alterations, peripheral and axial arthritis, as well as a variable group of other peri-articular disorders. Type 1, or pauciarticular, peripheral arthritis generally coincides with IBD exacerbations, while type 2, or polyarticular, peripheral arthritis follows an independent course from IBD. Axial in…

musculoskeletal diseasesmedicine.medical_specialtyAnkylosing spondylitisHepatologyEnteropathic arthropathybusiness.industryGastroenterologySacroiliitisArthritismedicine.diseaseGastroenterologyInflammatory bowel diseaseAsymptomaticUlcerative colitisdigestive system diseasesInfliximabInternal medicinemedicinemedicine.symptombusinessmedicine.drugGastroenterología y Hepatología
researchProduct

Anti-TNF-Antikörper zur Therapie von entzündlichen Darmstenosen bei Morbus Crohn

2003

Stenoses are a frequent complication in patients with Crohn's disease and represent a major diagnostic and therapeutic challenge. The proper assessment of the nature of a stenosis as inflammatory or fibrotic is critical for appropriate treatment, since symptomatic fibrotic stenoses require surgical resection. Standard diagnostic procedures to assess the nature of a stenosis include endoscopy, conventional contrast radiography and magnetic resonance tomography. Recent data suggest, that the positron-emission-tomography possesses a high sensitivity and specificity to confirm inflammatory activity in the bowel. The recombinant monoclonal anti-TNF-antibody Infliximab (Remicade) has been approve…

musculoskeletal diseasesmedicine.medical_specialtyCrohn's diseasemedicine.diagnostic_testbusiness.industryGastroenterologyColonoscopyRetrospective cohort studymedicine.diseaseGastroenterologyAsymptomaticInfliximabSurgerystomatognathic diseasesStenosisInternal medicinemedicinemedicine.symptombusinessComplicationAbscessmedicine.drugZeitschrift für Gastroenterologie
researchProduct

Clinical and economic impact of infliximab one-hour infusion protocol in patients with inflammatory bowel diseases: A multicenter study

2017

AIM To assess the impact of short infliximab (IFX) infusion on hospital resource utilization and costs. METHODS All inflammatory bowel diseases (IBD) patients who received IFX 1 h infusion from March 2007 to September 2014 in eight centers from Southern Italy were included in the analysis. Demographic, clinical and infusion related data were collected. The potential benefits related to the short infusion protocol were assessed both in terms of time saving and increased infusion unit capacity. In addition, indirect patient-related cost savings were evaluated. RESULTS One hundred and twenty-five patients were recruited (64 with ulcerative colitis and 61 with Crohn’s disease). Median duration …

musculoskeletal diseasesmedicine.medical_specialtyObservational StudyCost savings03 medical and health sciences0302 clinical medicineInternal medicinemedicineIn patient030212 general & internal medicineEconomic impact analysisskin and connective tissue diseasesProtocol (science)business.industryInflammatory Bowel DiseasesOne-hour infusionInfliximabInfliximabMulticenter studyCost savingsstomatognathic diseasesEconomic impactMulticenter studyPhysical therapy030211 gastroenterology & hepatologybusinessmedicine.drugWorld Journal of Gastrointestinal Pharmacology and Therapeutics
researchProduct